We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Accelerating Drug Discovery and Safety Studies on SyncroPatch 384, User Perspectives
Webinar

Accelerating Drug Discovery and Safety Studies on SyncroPatch 384, User Perspectives

Accelerating Drug Discovery and Safety Studies on SyncroPatch 384, User Perspectives
Webinar

Accelerating Drug Discovery and Safety Studies on SyncroPatch 384, User Perspectives

Dr Ciria Hernandez, MD, Ph.D
Dr Ciria Hernandez, MD, Ph.D
Assistant Research Scientist, University of Michigan Life Sciences Institute
Yuri Kuryshev
Yuri Kuryshev
Principal Scientist, Charles River Laboratories

In this webinar there will be two speakers discussing:

Title:

High-Throughput Functional Evaluation of Melanocortin Compounds at the MC4R-Kir7.1 Complex: Biased Signaling at the Melanocortin 4 Receptor

Title:

CiPA Based Evaluation of Proarrhythmia 

Watch now to learn about:

  • Melanocortin 4 receptors (MC4R) are G-protein coupled receptors (GPCR)
  • Loss-of-function MC4R mutation are linked to early-onset syndromic obesity.
  • MC4R is the first GPCR reported to functionally directly interact with the inward rectifier potassium channel Kir7.1.
  • Evaluation of validated channel assays and applied them to several drugs with questionable proarrhythmic safety.
  • Applying the CiPA Approach to Evaluate Cardiac Proarrhythmia Risk ofsome Antimalarials Used Off-label in the First Wave of COVID-19


Advertisement